Released on March 01, 2015

The mammalian target of rapamycin (mTOR) inhibitor sirolimus is effective in reducing incidence of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Agents that inhibit the mTOR pathway are known to be associated with significant and potentially...

Released on February 25, 2015

Background: Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy.  The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice...

Released on February 01, 2015

Purpose: To better understand the indirect effects of standard courses of radiation therapy (RT) on distant tissue toxicity, we evaluated the frequency, course, and health and economic burden of regimen-related diarrhea in a large, multinational group of patients who were being treated for...

Released on December 05, 2014

Regimen-related toxicities remain a priority concern within the field of supportive care in cancer. Despite this, many forms of toxicity are under reported and consequently poorly characterised. Although there have been significant improvements in our understanding of regimen-related toxicities...

Released on December 01, 2014

Background: Fatigue is a common side effect of cancer (CA) treatment. We used a novel analytical method to identify and validate a specific gene cluster that is predictive of fatigue risk in prostate cancer patients (PCP) treated with radiotherapy (RT). Methods: A total of 44 PCP were...

Released on November 04, 2014

Objectives: Oral Mucositis (OM) is a painful complication of radiation therapy (RT) for head and neck cancer (H&NC).  OM can compromise nurtrition, require opioid analgesics and hospitalization for pain control, and lead to treatment interruptions.  Based on the role of...

Released on October 01, 2014

Background: Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance.  Epidemiology remains poorly described, and effects of multi-cycle regimens have not been investigated...

Released on September 01, 2014

Introduction: Oral mucositis remains a common, symptomatically devastating toxicity of common drug and radiation regimens used to treat cancer.  The current limited treatment options are likely to be supplemented by an active pipeline in which innovative compounds are being developed which...

Released on May 01, 2014

Background: The objective of this trial was to determine how a mucoadhesive hydrogel (MuGard), a marketed medical device, would fare when tested with the strictness of a conventional multi-institutional, double-blind, randomized, placebo-contolled study format. Methods: A total of 120 subjects...

Released on April 10, 2014

Free radicals produced during cancer radiotherapy often leads to dermatitis, with the insult ranging from mild erythema to moist desquamation and ulceration. This toxicity can be dose limiting and promote chronic complications, such as fibrosis and wound recurrence. The purpose of this study was...